Shaun G Goodman

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

J Wouter Jukema, Deepak L. Bhatt, Deepak L Bhatt, 2018, The New England journal of medicine.

Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

L. Deckelbaum, P. Ridker, S. Pocock, 2020, American heart journal.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Deepak L. Bhatt, R. Diaz, H. White, 2018, New England Journal of Medicine.

Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

R. Pordy, M. Scemama, J. Mcginniss, 2024, Journal of Clinical Lipidology.

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

L. Milani, B. Nordestgaard, K. Hveem, 2023, Critical care explorations.

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial†

K. Mahaffey, P. Tricoci, G. Steg, 2019, Journal of Clinical Lipidology.

Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronarySyndrome

M. Szarek, A. Moryusef, R. Pordy, 2022 .

Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.

B. Chaitman, W. Kostis, M. Bertolet, 2023, The New England journal of medicine.